Sentence: This study evaluated the safety and efficacy of inotuzumab ozogamicin ( INO ) , a targeted humanized anti-CD22 antibody conjugated to calicheamicin , plus rituximab ( R-INO ) every 3 weeks , up to six cycles , followed by high dose therapy and autologous stem cell transplant ( HDT-aSCT ) in patients with high-risk relapsed/refractory diffuse large B-cell lymphoma ( DLBCL ) .
Drug combination annotation:
[{'class': 'COMB', 'spans': ['inotuzumab', 'rituximab', 'HDT-aSCT'], 'is_context_needed': True}]